Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review

• The FDA has accepted Argenx SE's (NASDAQ: ARGX) Biologics License Application for subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG).

• Under the Priority Review status, the FDA has granted a Prescription Drug User Fee Act (PDUFA) target action date of March 20, 2023.

• SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme Therapeutics Inc's (NASDAQ: HALO) Enhanze drug delivery technology that facilitates the SC administration of biologics that are typically administered via intravenous (IV) infusion.

• Related: Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike.

• The BLA submission is supported by data from the Phase 3 ADAPT-SC study.

• ADAPT-SC met its primary endpoint of total IgG reduction from baseline at day 29, demonstrating noninferiority of SC efgartigimod to Vyvgart.

• Patients treated with SC efgartigimod achieved a mean total IgG reduction of 66.4%, compared to a 62.2% reduction with Vyvgart.

• Price Action: ARGX shares are down 1.07% at $370.33 premarket on the last check Tuesday.

See more from Benzinga

• Novavax Terminates Agreement With GAVI Alliance For Sale Of Its COVID-19 Vaccines

• Agilent Beats On Q4 Earnings, Issues Mixed Guidance

• Bill Gates Says This Could Lead To Civil War And 'Bring It All To An End'

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.